Expansion Therapeutics

Jupiter, FL · Founded 2016 · Biotech · Private

Small molecule therapeutics that target RNA to treat expansion repeat disorders

Claim this profile

Follows are private to you and power your alerts

Updated · expansionrx.com

Sector
Biotech
Headquarters
Jupiter, FL
Founded
2016
Latest Form D
$48M, Oct 2021
Total capital
$73.6M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$73.6M
3 Form D · last Oct 2021
60 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
2 pending · first 2021
Rank in peer group#481 of 1449

Capital timeline

201620172018201920202021FEDERAL ↑EQUITY ↓Cumulative $73.6M1st Form D$250K2nd Form D$25.3M3rd Form D$48M
201620172018201920202021FEDERAL ↑EQUITY ↓Cumulative $73.6M1st Form D$250K2nd Form D$25.3M3rd Form D$48M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$48M
  • Private capital raisedForm D · SEC · 2nd filing$25.3M
  • Private capital raisedForm D · SEC · 1st filing$250K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Matthew DisneyResearcherDirectorLinked by 1 patent
  • Andy Phillips, Ph.D.DirectorNamed in SEC Form D filings
  • Beth Seidenberg, M.D.DirectorNamed in SEC Form D filings
  • Campbell Murray, M.B.B.S., M.B.A.DirectorNamed in SEC Form D filings
  • Jason HaflerDirectorNamed in SEC Form D filings
  • Jason Hafler, Ph.D.DirectorNamed in SEC Form D filings
Show all 16 people
  • Kevin ForrestExecutive Officer, DirectorNamed in SEC Form D filings
  • Kevin Forrest, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
  • Laura Tadvalkar, Ph.D.DirectorNamed in SEC Form D filings
  • Matthew Disney, Ph.D.DirectorNamed in SEC Form D filings
  • Paul StoneExecutive OfficerNamed in SEC Form D filings
  • Renato Skerlj, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
  • Scott RocklageExecutive Officer, DirectorNamed in SEC Form D filings
  • Scott Rocklage, Ph.D.DirectorNamed in SEC Form D filings
  • Yujiro HataDirectorNamed in SEC Form D filings
  • Yujiro Hata, M.B.A.DirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 3
  • Larimar TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Nocion Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • Comanche BiopharmaSimilar federal contract value in Biotech · null in contracts
  • SepternaSimilar federal contract value in Biotech · null in contracts
  • Blueprint MedicinesSimilar federal contract value in Biotech · null in contracts
  • Spark Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .